share_log

UroGen Pharma Ltd | 8-K: UroGen Pharma Ahead of Schedule to Complete UGN-102 NDA Submission and Reports 2024 Second Quarter Financial Results and Business Highlights

UroGen Pharma Ltd | 8-K: UroGen Pharma Ahead of Schedule to Complete UGN-102 NDA Submission and Reports 2024 Second Quarter Financial Results and Business Highlights

烏龍製藥 | 8-K:UroGen Pharma 提前完成 UGN-102 保密協議的提交和報告 2024 年第二季度財務業績和業務亮點
美股SEC公告 ·  08/13 08:07
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息